Efficacy and Safety of Anti-tuberculosis Drugs for the Treatment of Multidrug Resistance-tuberculosis: a Network Meta-analysis

Background Second-line anti-tuberculosis drugs are widely used in clinic for multi-drug resistant tuberculosis (MDR-TB) . At present, there are several reticulated meta-analyses investigating them, but the effect is not very satisfactory. Objective To systematically evaluate the efficacy and safety...

Full description

Saved in:
Bibliographic Details
Published inZhongguo quanke yixue Vol. 26; no. 5; pp. 598 - 606
Main Author CHEN Tao, FAN Qingze, SUN Xuemei, YU Yongqi, LUO Hongli
Format Journal Article
LanguageChinese
Published Chinese General Practice Publishing House Co., Ltd 01.02.2023
Subjects
tuberculosis, multidrug-resistant|moxifloxacin|levofloxacin|linezolid|clofazimine|bedaquiline|network meta-analysis
Online AccessGet full text

Cover

More Information
Summary:Background Second-line anti-tuberculosis drugs are widely used in clinic for multi-drug resistant tuberculosis (MDR-TB) . At present, there are several reticulated meta-analyses investigating them, but the effect is not very satisfactory. Objective To systematically evaluate the efficacy and safety of five anti-tuberculosis chemotherapy regimens in the treatment of MDR-TB. Methods Randomized controlled trials (RCTs) on anti-tuberculosis drug for MDR-TB were retrieved from PubMed, Medline, Web of Science, VIP, and Wanfang data from January 2010 to March 2022. The experimental group was treated with individualized treatment combined with moxifloxacin (Mfx) , levofloxacin (Lfx) , linezolid (Lzd) , clofazimine (Cfz) and bedaquiline (Bdq) . The control group was treated with individualized treatment combined with placebo or Lfx. After literature screening and data extraction, quality assessment was performed using the risk of bias assessment tool provided by the Cochrane system evaluator handbook 5.1.0. Bayesian n
ISSN:1007-9572
DOI:10.12114/j.issn.1007-9572.2022.0530